Drug intelligence / Profile preview

encapsulated faecal microbiome transfer

Development stage: Unknown
Lead developer: The University of Auckland
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Encapsulated faecal microbiome transfer is a live biotherapeutic product (LBP) consisting of donor-derived intestinal microbiota and metabolites processed into an oral capsule. Developed by the University of Auckland, it is designed to restore the disrupted gut microbiome and colonization resistance in patients with recurrent or refractory *Clostridioides difficile* infection (CDI). The therapy works by introducing a complex community of healthy microorganisms to displace pathogens and re-establish microbial diversity. It has been evaluated in randomized clinical trials in New Zealand, comparing its efficacy for sustained cure against standard-of-care oral vancomycin.

Other names: encapsulated FMToral faecal microbiome transfer

Beyond the preview

Go deeper on encapsulated faecal microbiome transfer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on encapsulated faecal microbiome transfer.

Explore the full profile